RxDoctor Payments Data

Raymond Overstreet, MD

Psychiatry · Columbus, MSNPI 1447350541

Payments from drug & device makers

$978in general payments, 2019–2025

Across 55 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$220
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$217
  • Johnson & Johnson$103
  • Takeda Pharmaceuticals U.S.A., Inc.$90
  • Otsuka America Pharmaceutical, Inc.$84
  • Sunovion Pharmaceuticals Inc.$51
  • plus $212 from 8 others

What the payments were for

  • Food & beverage$95197%
  • Education$273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$978 in reported general payments places this provider in the 55th percentile of 219 psychiatry providers in Mississippi.

See all psychiatry providers in Mississippi

Medicare billing

Part B allowed, 2024
$13,765
Medicare patients
92
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate71$217,324
Invega TrinzaPaliperidone Palmitate26$203,695
AustedoDeutetrabenazine26$171,949
Abilify MaintenaAripiprazole25$71,790
UzedyRisperidone34$70,499
Risperdal ConstaRisperidone Microspheres31$55,148
VraylarCariprazine Hcl16$24,128
TrintellixVortioxetine Hydrobromide35$21,980
Lurasidone Hcl38$15,803
Aripiprazole196$13,326
Tiagabine Hcl12$7,694
Chlorpromazine Hcl13$5,708
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine173$5,705
Paliperidone ErPaliperidone24$4,981
Clozapine23$3,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$103$476,168128 claims
Teva Pharmaceuticals USA, Inc.Austedo, Uzedy$220$242,44860 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$84$71,79025 claims
AbbVieVraylar$34$24,12816 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$90$21,98035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 219 psychiatry providers in Mississippi.

Other psychiatry in Columbus

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →